Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 1
Submit an article Journal homepage
807
Views
20
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer

Thor ChalmerCenter for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
,
Thomas P AlmdalCenter for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
,
Tina VilsbøllCenter for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
&
Filip K KnopCenter for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark;University of Copenhagen, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, Copenhagen, Denmark;Gentofte Hospital, University of Copenhagen, Kildegårdsvej 28, 2900 Hellerup, Denmark+45 3867 8132; +45 3867 7661; [email protected]
, MD PhD (Associate Professor, Consultant, Director of Center for Diabetes Research)
Pages 171-180 | Published online: 03 Nov 2014

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Niels B. Dalsgaard, Andreas Brønden, Tina Vilsbøll & Filip K. Knop. (2017) Cardiovascular safety and benefits of GLP-1 receptor agonists. Expert Opinion on Drug Safety 16:3, pages 351-363.
Read now
Chin-Hsiao Tseng, Kuo-Yang Lee & Farn-Hsuan Tseng. (2015) An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. Journal of Environmental Science and Health, Part C 33:1, pages 67-124.
Read now

Articles from other publishers (18)

Fuxun Yang, Xiaoxiu Luo, Jiajia Li, Yu Lei, Fan Zeng, Xiaobo Huang, Yunping Lan & Rongan Liu. (2022) Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases. Biomedicine & Pharmacotherapy 152, pages 113236.
Crossref
Aljawhara R AlSaadoun, Tariq R AlSaadoun & Abdullah K Al Ghumlas. (2022) Liraglutide Overdose-Induced Acute Pancreatitis. Cureus.
Crossref
Taoreed Adegoke Azeez, Sharif Adeniyi Folorunso, Chinedu Eguzozie & Adeleke Adedapo Adegboyega. (2021) Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental?. Forum of Clinical Oncology 12:1, pages 74-81.
Crossref
Jang Won Son & Sungrae Kim. (2020) Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. Diabetes & Metabolism Journal 44:6, pages 802-818.
Crossref
Yufang Liu, Xiaomei Zhang, Sanbao Chai, Xin Zhao & Linong Ji. (2019) Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. Journal of Diabetes Research 2019, pages 1-10.
Crossref
Silvia Garelli, Nicola Salituro, Giulia M. Pontesilli, Luigi Ricciardiello, Valentina Vicennati & Uberto Pagotto. 2019. Encyclopedia of Endocrine Diseases. Encyclopedia of Endocrine Diseases 464 472 .
Xuejing Li, Suhui Qie, Xianying Wang, Yingying Zheng, Yang Liu & Guoqiang Liu. (2018) The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. Endocrine 62:3, pages 535-545.
Crossref
Angélique Gajahi Soudahome, Aurélie Catan, Pierre Giraud, Sandrine Assouan Kouao, Alexis Guerin-Dubourg, Xavier Debussche, Nathalie Le Moullec, Emmanuel Bourdon, Susana B. Bravo, Beatriz Paradela-Dobarro, Ezequiel Álvarez, Olivier Meilhac, Philippe Rondeau & Joël Couprie. (2018) Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide. Journal of Biological Chemistry 293:13, pages 4778-4791.
Crossref
Gitanjali Srivastava & Caroline M. Apovian. (2017) Current pharmacotherapy for obesity. Nature Reviews Endocrinology 14:1, pages 12-24.
Crossref
Y. Nakatani, M. Maeda, M. Matsumura, R. Shimizu, N. Banba, Y. Aso, T. Yasu & H. Harasawa. (2017) Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes & Metabolism 43:5, pages 430-437.
Crossref
Vanita R Aroda, Stephen C Bain, Bertrand Cariou, Milivoj Piletič, Ludger Rose, Mads Axelsen, Everton Rowe & J Hans DeVries. (2017) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology 5:5, pages 355-366.
Crossref
I. Vardarli & C. Özcelik. (2016) LEADER-Studie: 22 %ige Senkung der kardiovaskulären MortalitätLEADER study: 22 % reduction in cardiovascular mortality. Der Kardiologe 10:6, pages 339-340.
Crossref
. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 375:18, pages 1797-1799.
Crossref
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F.E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R. Poulter, Lasse S. Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal & John B. Buse. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 375:4, pages 311-322.
Crossref
Midhat H. Abdulreda, Rayner Rodriguez-Diaz, Alejandro Caicedo & Per-Olof Berggren. (2016) Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model. Cell Metabolism 23:3, pages 541-546.
Crossref
T. Jorsal, J. Rungby, F. K. Knop & T. Vilsbøll. (2015) GLP-1 and Amylin in the Treatment of Obesity. Current Diabetes Reports 16:1.
Crossref
Brian A. BaldoBrian A. Baldo. 2016. Safety of Biologics Therapy. Safety of Biologics Therapy 309 400 .
Ben J. Jones & Stephen R. Bloom. (2015) The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. Drugs 75:9, pages 935-945.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.